SCHEMBL6557376

SCHEMBL6557376

O=S(=O)(Cl)c1ccc(C=Cc2ccc(S(=O)(=O)Cl)cc2)cc1

nearest known ligand 0.52

Predicted protein targets (top 11)

geneUniProtsupporting neighboursconfidence
TDP1 Q9NUW8 2/20 0.52
ALDH1A1 P00352 1/20 0.52
HSD17B10 Q99714 1/20 0.52
HTR2A P28223 4/20 0.43
KCNH2 Q12809 2/20 0.43
AHR P35869 1/20 0.41
PTGS2 P35354 2/20 0.38
MAOB P27338 1/20 0.38
NPC1 O15118 1/20 0.38
MAPT P10636 1/20 0.38
RAB9A P51151 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6557373 1.00 TDP1 (0.52) TDP1ALDH1A1HSD17B10HTR2AKCNH2
Piperazine SCHEMBL6559517 0.87 ALDH1A1 (0.41) TDP1ALDH1A1HSD17B10HTR2AKCNH2
SCHEMBL28814169 0.86 ALDH1A1 (0.44) TDP1ALDH1A1HSD17B10HTR2AKCNH2
SCHEMBL14533597 0.84 ALDH1A1 (0.50) TDP1ALDH1A1HSD17B10NPC1MAPT
SCHEMBL651902 0.83 ALDH1A1 (0.71) TDP1ALDH1A1HSD17B10
SCHEMBL351760 0.82 ALDH1A1 (0.50) TDP1ALDH1A1HSD17B10PTGS2RAB9A
SCHEMBL28814657 0.81 ALDH1A1 (0.40) TDP1ALDH1A1HSD17B10HTR2AKCNH2
SCHEMBL1375276 0.81 HCAR2 (0.57) TDP1ALDH1A1HSD17B10MAOBNPC1
SCHEMBL1373939 0.81 HCAR2 (0.57) TDP1ALDH1A1HSD17B10MAOBNPC1
Di(Hydroxyethyl)Ether SCHEMBL6558436 0.81 NPC1 (0.38) TDP1ALDH1A1HSD17B10HTR2AKCNH2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250376543-A1 HYALURONIC ACID-COLLAGEN COPOLYMER COMPOSITIONS AND MEDICAL APPLICATIONS THEREOF SHANGHAI QISHENG BIOLOGICAL PREPARATION CO LTD (CN) 2025-12-11 US disclosed
US-12304974-B2 Hyaluronic acid-collagen copolymer compositions and medical applications thereof SHANGHAI QISHENG BIOLOGICAL PREPARATION CO., LTD. (CN) 2025-05-20 US disclosed
WO-2024163315-A2 DERIVATIZED COLLAGEN-HYALURONIC ACID BASED IMPLANTS FOR SUSTAINED DELIVERY OF OPHTHALMIC DRUGS DEVORE DALE (US) 2024-08-08 WO disclosed
US-20240252446-A1 DERIVATIZED COLLAGEN-HYALURONIC ACID BASED IMPLANTS FOR SUSTAINED DELIVERY OF OPHTHALMIC DRUGS SUSTAINED DRUG DELIVERY LLC 2024-08-01 US disclosed
US-20230203207-A1 HYALURONIC ACID-COLLAGEN COPOLYMER COMPOSITIONS AND MEDICAL APPLICATIONS THEREOF SHANGHAI QISHENG BIOLOGICAL PREPARATION CO., LTD. (CN) 2023-06-29 US disclosed
US-10869884-B2 Cyclodextrin based polymers, methods, compositions and applications thereof ATEN PORUS LIFESCIENCES (IN) 2020-12-22 US disclosed
US-20190209605-A1 CYCLODEXTRIN BASED POLYMERS, METHODS, COMPOSITIONS AND APPLICATIONS THEREOF ATEN PORUS LIFESCIENCES (IN) 2019-07-11 US disclosed
US-6835718-B2 Biocleavable micelle compositions for use as drug carriers KK BIOMED CORPORATION 2004-12-28 US disclosed
EP-1183538-B1 CYCLODEXTRIN POLYMERS FOR USE AS DRUG CARRIERS KOSAK KEN M (US) 2004-04-14 EP disclosed
EP-0916394-B1 Method of manufacturing modified particles and manufacturing device therefor SHARP KK (JP) 2004-03-10 EP disclosed
US-20010021703-A1 Biocleavable micelle compositions for use as drug carriers KK BIOMED CORPORATION 2001-09-13 US disclosed
US-6194487-B1 EXPOSURE OF PARTICLES TO SUPERSATURATED VAPOR OF MONOMERS, CONDENSATION AND POLYMERIZATION ON THE SURFACE SHARP KABUSHIKI KAISHA (JP) 2001-02-27 US disclosed
WO-2000040962-A1 CYCLODEXTRIN POLYMERS FOR USE AS DRUG CARRIERS KOSAK KEN M (US) 2000-07-13 WO disclosed
US-6048736-A PRODUCING A CONTROLLED DRUG DELIVERY SYSTEM; MIXING POLYMERS WITH A VARIETY OF COMPOUNDS, CROSS-LINKING THE POLYMERS WITH BIOCOMPATIBLE CLEAVAGE SITES, INCUBATE WITH COMPOUND WHICH ACTIVATES CONTROLLED RELEASE KOSAK KENNETH M (US) 2000-04-11 US disclosed
EP-0916394-A2 Method of manufacturing modified particles and manufacturing device therefor Sharp Kabushiki Kaisha (JP) 1999-05-19 EP disclosed
WO-1991002040-A1 CYCLODEXTRIN LABELS FOR NUCLEIC ACID AND BIOCHEMICAL ANALYSIS KOSAK KENNETH M (US) 1991-02-21 WO disclosed
US-4883864-A COUPLED AND FREE AMINE GROUPS CAPPED WITH UREA OR AMIDE GROUPS, EYE SURGERY MINNESOTA MINING AND MANUFACTURING COMPANY (US) 1989-11-28 US disclosed
US-4851513-A Viscoelastic collagen solution for opthalmic use and method of preparation MINNESOTA MINING AND MANUFACTURING COMPANY (US) 1989-07-25 US disclosed
US-4713446-A COLLAGEN COUPLED TO CARBONYL OR SULFONYL GROUPS MINNESOTA MINING AND MANUFACTURING COMPANY (US) 1987-12-15 US disclosed
EP-0214853-A2 Viscoelastic collagen solution for ophthalmic use and method of preparation MINNESOTA MINING AND MANUFACTURING COMPANY (US) 1987-03-18 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10869884-B2 Cyclodextrin based polymers, methods, compositions and applications thereof NPC1L1, CETP, LIPA TDP1 3804/4885ALDH1A1 2394/4885HSD17B10 378/4885
US-20190209605-A1 CYCLODEXTRIN BASED POLYMERS, METHODS, COMPOSITIONS AND APPLICATIONS THEREOF NPC1L1, CETP, LIPA TDP1 3804/4885ALDH1A1 2394/4885HSD17B10 378/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.